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To address the possibility that chemicals could
threaten the health of humans and wildlife
through their interaction with the endocrine
system, the Organisation for Economic
Cooperation and Development (OECD) ini-
tiated a high-priority activity in 1997 to
develop guidelines for the testing of potential
endocrine-active chemicals (OECD 1998).
This OECD activity is managed by the Task
Force on Endocrine Disrupters Testing and
Assessment as part of the OECD Test
Guidelines Programme and was coordinated
by a Validation Management Group (VMG).
The VMG included experts from eight OECD
member countries with expertise in toxicology,
test development and validation, endocrinol-
ogy, regulatory toxicology, and biostatistics.
This report focuses on the OECD
Hershberger validation program as an in vivo
androgenic screen [i.e., androgen receptor ago-
nists, androgen receptor antagonists, and
5α-reductase inhibitors preventing testosterone
(T) conversion to the more potent dihydro-
testosterone]. This fulﬁlls, in part, the priorities
to develop and validate screens and tests for
estrogen, androgen, and thyroid modes of
action [OECD 1998; U.S. Environmental
Protection Agency (U.S. EPA) 1998] by
providing a screen for androgens and anti-
androgens. The advantages of the Hershberger
bioassay are several: the tissues are the natural
targets for androgens, the tissue growth
response is relatively rapid, the tissue weights
are quantitative, and no specialized facilities or
equipment is necessary.
The need for an androgenic screen is based
on the necessity for androgens in the in utero
development of the male reproductive tract
(Jost 1947, 1953). Antiandrogens and
inhibitors of androgen synthesis have been
known for more than 40 years to elicit frank
male reproductive tract malformations (Bloch
et al. 1971; Goldman 1971; Neumann et al.
1966, 1970). In the Hershberger bioassay, if
the endogenous androgen is removed by castra-
tion, then an exogenous androgen source is
needed for target tissues to grow and gain
weight. Chemicals that act as agonists may be
identiﬁed if they cause statistically signiﬁcant
increases in the weights of the target androgen-
dependent tissues. Alternatively, chemicals
may be identiﬁed as antagonists if they cause
statistically signiﬁcant decreases in the stimu-
lated target tissue weights increase when the
chemicals are co-administered with a potent
androgen such as testosterone propionate (TP).
The surgically castrated male rat assay for
androgens has existed in various forms for
more than 70 years (Korenchevsky 1932;
Korenchevsky et al. 1932). This original work
used tissues such as the ventral prostate (VP),
seminal vesicles and coagulating glands
(SVCG), and glans penis (GP). Other investi-
gations employed other tissues such as the
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The Organisation for Economic Cooperation and Development (OECD) has completed phase 1 of
the Hershberger validation intended to identify in vivo activity of suspected androgens and anti-
androgens. Seventeen laboratories from 7 countries participated in phase 1, and results were collated
and evaluated by the OECD with the support of an international committee of experts. Five
androgen-responsive tissues (ventral prostate, paired seminal vesicles and coagulating glands, levator
ani and bulbocavernosus muscles, glans penis, and paired Cowper’s or bulbourethral glands) were
evaluated. The standardized protocols used selected doses of a reference androgen, testosterone
propionate (TP), and an antiandrogen, flutamide (FLU). All laboratories successfully detected
TP-stimulated increases in androgen-responsive tissue weight and decreases in TP-stimulated tissue
weights when FLU was co-administered. The standardized protocols performed well under a variety
of conditions (e.g., strain, diet, housing protocol, bedding). There was good agreement among labo-
ratories with regard to the TP doses inducing signiﬁcant increases in tissue weights and the FLU
doses decreasing TP-stimulated tissue weights. Several additional procedures (e.g., weighing of the
dorsolateral prostate and ﬁxation of tissues before weighing) and serum component measurements
(e.g., luteinizing hormone) were also included by some laboratories to assess their potential utility.
The results indicated that the OECD Hershberger protocol was robust, reproducible, and transfer-
able across laboratories. Based on this phase 1 validation study, the protocols have been reﬁned, and
the next phase of the OECD validation program will test the protocol with selected doses of weak
androgen agonists, androgen antagonists, a 5α-reductase inhibitor, and chemicals having no andro-
genic activity. Key words: androgen, antiandrogen, bulbocavernosus, Cowper’s glands, endocrine dis-
ruption, ﬂutamide, glans penis, Hershberger, levator ani, seminal vesicles, testosterone propionate,
validation, ventral prostate. Environ Health Perspect 114:1259–1265 (2006). doi:10.1289/ehp.8751
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assay was later modified to assess the related
myotrophic action by measuring the levator
ani and bulbocavernosus muscles (LABC)
(Eisenberg and Gordan 1950; Eisenberg et al.
1949; Hershberger et al. 1953). Then, the
assay was adapted for androgen antagonists
such as ﬂutamide (FLU) (Peets et al. 1973) by
measuring interference with the action of a
co-administered reference androgen. More
recently, the assay has been demonstrated
with weaker antagonists, such as p,p´-DDE
(p,p´-dichlorodiphenyldichloroethylene;
O’Connor et al. 1999) and linuron (Lambright
et al. 2000).
Protocols for the pharmaceutical industry
(e.g., Dorfman 1969a, 1969b) and a regulatory
screen for steroidal androgens (Hilgar and
Vollmer 1964) have been published. More
recently, Ashby and Lefevre (2000), Yamada
et al. (2000), and Yamasaki et al. (2001) have
investigated protocol variables with weak
antiandrogens. However, no internationally
standardized protocol is available, and there
has been no clear consensus on which male
reproductive tract tissues to include.
The objective of the OECD Hershberger
assay program is to develop a new, validated test
guideline. The validation of the Hershberger
assay was designed to be carried out in phases.
Phase 1, reported here, was designed to test,
reﬁne, and standardize the Hershberger assay
using high-potency reference agonist and
antagonist; to provide data on intra- and inter-
laboratory variability; and to assess the feasibil-
ity and utility of several other proposed end
points and procedures.
Design of Phase 1
The objectives of the ﬁrst phase of the OECD
validation of the Hershberger bioassay were to
a) demonstrate the reproducibility and sensi-
tivity of the responses of ﬁve male sex acces-
sory tissues to the action of a reference
androgen, TP, hereafter phase 1A; b) assess
the utility, reproducibility, and sensitivity of
various other measured end points within and
among participating laboratories in response
to the action of TP; c) study the interaction of
reference TP doses with a reference androgen
antagonist, FLU, on the sex accessory tissues
and other end points, hereafter phase 1B; and
d) select standard reference doses of TP and
FLU for future studies with weakly potent
agonists, antagonists, and nonandrogenic test
substances.
Standardized protocol. The VMG and
other experts drafted a set of standardized pro-
tocol conditions for phase 1A. Those protocol
conditions are provided in Supplemental
Material (http://www.ehponline.org/docs/
2006/8751/suppl.pdf). After phase 1A, early
castration [before postnatal day (PND) 40] was
found to prevent complete preputial separation
that complicated the GP dissection. For
phase 1B, castration was delayed to approxi-
mately PND 42. This standardized protocol
called for the humane treatment of the ani-
mals and for the alleviation of suffering under
OECD guidelines. Draft laboratory protocols,
ﬁnal laboratory protocols, and ﬁnal laboratory
reports were reviewed for compliance with the
standardized protocol and any deviations.
Other parameters such as housing, bed-
ding, and diet were not speciﬁed and were left
to the preferences of the participating labora-
tories. As the Hershberger bioassay is intended 
to be a rapid screen for a potentially large
number of chemicals, too rigorous and
detailed standardization would likely constrain
or even prevent practice in many of the
OECD member countries.
Dissection guidance and training. The
lead laboratory (the U.S. EPA laboratory of
L.E.G.), with input from other experts, devel-
oped a guidance manual to standardize the
dissection procedures for the male sex acces-
sory tissues of interest. The original manual
included literature references and figures as
well as sets of detailed color photographs
illustrating the step-by-step dissection of each
tissue [Supplemental Material (http://www.
ehponline.org/docs/2006/8751/suppl.pdf)].
Two training sessions were provided for the pro-
sectors from the participating laboratories: one
session was held at the lead laboratory, and the
other at laboratory 1 (the laboratories were
assigned random code numbers, which do not
follow their names or countries of origin).
Participating laboratories. A total of
17 laboratories from France, Germany,
Denmark, Japan, Korea, the United Kingdom,
and the United States participated in phase 1.
All laboratories participated on a voluntary
and self-supporting basis and included labora-
tories with experience conducting the assay
and others without experience before this
study. Table 1 describes the laboratory meas-
urements, and other laboratory conditions are
described in Supplemental Material (http://
www.ehponline.org/docs/2006/8751/suppl.
pdf). In-life testing for phase 1A (all laborato-
ries) occurred during the period June 2000
through January 2001; the in-life portion of
phase 1B (seven laboratories) was between
March 2001 and June 2001.
Chemicals and selected doses. The refer-
ence androgen agonist (TP; CASRN 57-82-5)
was from Sigma-Aldrich (St. Louis, MO,
USA; 99.9% pure), and the reference an-
drogen antagonist (FLU) (CASRN 13311-84-
7) was from Salutas Pharma (Barleben,
Germany; 99.9% pure). Single chemical lots
were purchased by a central chemical reposi-
tory at TNO (Netherlands Organisation for
Applied Scientific Research, Zeist, the
Netherlands), which distributed the chemicals
to all laboratories.
The doses of TP and FLU were speciﬁed in
order to assess test reproducibility among the
laboratories. The selected doses for phase 1A
were 0.1, 0.2, 0.4, 0.8, and 1.6 mg TP/kg-body
weight (bw)/day. In phase 1B, two doses of TP
were selected. To approximate the dose effec-
tive in 70% of subjects (ED70) for the LABC
and so that the VP, SVCG, and Cowper’s
glands (COWS) would have high absolute
and relative responses without approaching
their maximums, 0.4 mg TP/kg-bw/day was
selected. The lower concentration of 0.2 mg
TP/kg-bw/day was selected as the second dose.
The selected FLU dose series was 0.1, 0.3, 1.0,
3.0, and 10.0 mg/kg-bw/day. All doses were
prepared in corn oil, and the volumes to be
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Table 1. Measurements recorded by individual participating laboratories in phase 1 of the OECD
Hershberger validation program.
Laboratory
Dose response 123456789 1 0 1 2 1 3 1 4 1 5 1 6 1 7
TP dose response
Mandatory tissuesa Yb YYYYYYYYYYYYYYY
Kidney Y Y Y Y Y Y Y Y Y Y Y
Adrenals Y Y Y Y Y Y Y Y Y Y
Dorsolateral prostate Y Y
VP (ﬁxed) Y Y
Dorsolateral prostate (ﬁxed) Y Y Y
SVCG (ﬁxed) Y Y
COWS (ﬁxed) Y Y Y
Serum hormonesc YY Y
Untreated groupd YY
FLU dose response
Mandatory tissuesa YYY b YY b YYY b
Kidney Y Y Y Y Y Y
Adrenals Y Y Y Y Y
Dorsolateral prostate Y Y
Fixed tissues Ye Yf
Serum hormonesb Y
Y, yes.
aVP (fresh tissue, and ﬁxed), dorsolateral prostate, SVCG LABC, GP, COWS, daily body weights, and liver weights. bNo ﬁxed
VP weight recorded. cT and LH analyses in serum. dThese laboratories included an additional untreated control group (no
vehicle was administered to this group). eCOWSs were ﬁxed. fVP, SVCG, dorsolateral prostate, and COWS were ﬁxed.administered were calculated based upon the
daily body weights so as to maintain the
selected doses. In all cases, the doses were to be
administered for 10 consecutive days at
approximately 24-hr intervals.
Data reporting. Each participating labora-
tory received a standardized Excel spreadsheet
format for recording the data in a consistent
format and e-mail transmission to the OECD
Secretariat, lead laboratory, and other statisti-
cians. The spreadsheet recorded the laboratory
personnel, parameters such as diet and rat
strain as well as their suppliers and lots, proto-
col variables such as the dates of castration and
the initiation of treatment, caging practices,
and bedding. The spreadsheet contained indi-
vidual worksheets to record the randomization
procedures used to assign the animals to
dosage groups; to record the individual animal
numbers, daily body weights, times of admin-
istration, administration volumes, and any
clinical signs or observations for each dosage
group; and to record all mandatory and
optional end points measured, for example,
group and individual animal identification,
dates of necropsy, entry of preputial separation
observations. In addition to rapid transmis-
sion, the worksheets also provided the means
to quickly calculate basic means, standard
deviations, and coefﬁcients of variation (CVs)
to assist data audits. This proved essential for a
rapid assessment of possible entry errors or
identiﬁcation of possible issues, for example,
unusually large standard deviations for a
group, by the OECD Secretariat and the lead
laboratory. In addition, the organization and
format of the data in the worksheets allowed
rapid calculation of basic means, standard
deviations, and CVs to assist data audits and
data extraction into statistical programs.
Statistical analyses. The lead laboratory
calculated means, standard errors, and the
CVs for each end point using PROC MEANS
on SAS (version 6.08; SAS Institute Inc.,
Cary, NC, USA). Analyses of variances
(ANOVAs) for each laboratory were done
using PROC GLM, and then the laboratories
were pooled for each test substance. Data for
each end point also were analyzed as a two-
way ANOVA, with dose and laboratory as
main effects, so that the magnitudes of the
overall dose and laboratory effects, and their
interactions could be determined. Because the
CV for each androgen-dependent organ weight
was fairly constant as the means increased, the
standard deviations being proportional to the
mean, the data were log transformed. Analyses
were also conducted with body weight as a
covariate because this adjusts the analysis for
experimental variation from several sources,
such as a) differences in the size of the rats
from laboratory to laboratory, a large compo-
nent of which appeared to arise from the use of
different strains, and b) differences in the sizes
of the rats on study within a laboratory. R2 val-
ues for different effects were calculated to pro-
vide an indication of the strength of the
association for an effect with an end point.
Thus, the robustness of the dose response
across end points, the variation from laboratory
to laboratory, and to what degree the dose
responses vary among laboratories, as indicated
by the R2 for the laboratory by dose inter-
action, were analyzed. The analyses of the
lead laboratory were conﬁrmed by a separate,
independent statistician.
The Secretariat also conducted additional
statistical analyses of the data for the manda-
tory end points. Because the lead laboratory
procedures are based upon a pairwise t-test
comparison of several individual groups with
the single vehicle (phase 1A) or TP dose only
(phase 1B) control, Dunnett’s multiple com-
parison procedure for multiple pairwise
comparisons was employed (Dunnett 1955,
1964; Hsu 1996), using S-Plus (version 6.1;
Insightful Corp., Seattle, WA, USA). The
same estimate of pooled variance is used in
both tests, but in Dunnett’s test a different
critical value is used to account for multiple
comparisons. Due to the potential of treat-
ment related effects on the body weight,
analyses were performed with both the starting
and terminal body weights. Further, because
the number of groups influences the error
term in the Dunnett’s approach, for the TP
dose–response (phase 1A) untreated vehicle
controls, if performed, were excluded from the
Dunnett’s analyses, and for the FLU dose
response (phase 1B), the vehicle control
group, if performed, was excluded from the
Dunnett’s analyses. In addition, because the
same Dunnett’s approach with body weight as
a covariable was used for the uterotrophic
bioassay validation (Kanno et al. 2001, 2003),
it was judged that similar statistical analyses
should be available for both the Hershberger
and the uterotrophic validation programs.
The primary difference between the two
statistical approaches in practice is that the
analysis of covariance F-test followed by a t-test
comparison is slightly more liberal in achieving
statistical signiﬁcance. That is, single pairwise
comparisons may achieve statistical signiﬁcance
in some marginal cases where Dunnett’s multi-
ple comparisons do not. The results of both
analyses are reported here side by side in the
tables for the mandatory end points. Outliers
were observed in a few data sets (defined as
Studentized residuals > 4 or < –4), but these
outliers were included in all of the statistical
analyses results shown here.
Because only a log transformation was
used in the original analysis, the independent
analysis investigated the use of untransformed
data or a square-root transformation pro-
cedure. A normality test (Wilk-Shapiro) was
applied to assess whether the transformation
satisfied these model assumptions. The best
transformation was judged to be the one that
gave the largest (nonsigniﬁcant) p-value for the
normality test statistic.
Results were also compared using bench-
mark dose (BMD) methodology. In this case
the BMD was deﬁned as the dose at which the
mean response is increased by two standard
deviations over the mean response of the con-
trol group. This deﬁnition of the BMD allows
for better comparisons among end points with
inherently different variability. The Hill
model [Y (dose) = intercept + v × dosen/
(kn + dosen), where the intercept, v, k, and n
are parameters to be estimated] was ﬁt to the
data using the U.S. EPA BMD software
BMDS (version 1.3.1; U.S. EPA 2001). In
cases where the Hill model did not converge,
the high-dose group was iteratively dropped
until convergence was obtained. This method
was used because it was determined that most
of the convergence problems were due to a
flat dose–response relationship in the high-
dose region. The BMD calculations were
made using both the log-transformed data
and the transformation determined to be
most appropriate.
Results of Phase 1A: 
TP Dose Response
All laboratories provided the Excel spread
sheets containing all of their individual ani-
mal results and summaries of the protocol
conditions used. One laboratory inadvertently
administered TP in µg/kg-bw/day rather than
in mg/kg-bw/day doses, and no TP effect was
observed in any of the tissue weights. As a
result, the data submitted by this laboratory
have been omitted and are not included
in the data analyses or summary tables. The
laboratory means and standard deviations
for each tissue for phase 1A are provided
in Supplemental Material (http://www.
ehponline.org/docs/2006/8751/suppl.pdf).
VP results. There were statistically signiﬁ-
cant, dose-dependent increases in VP weights
in all laboratories. Even at the lowest dose of
0.1 mg TP/kg-bw/day, the VP weights dif-
fered signiﬁcantly from the controls, except in
laboratory 7 by both statistical approaches and
in laboratory 4 only by the Dunnett’s test.
The strain and weights of the animals at the
time of initiation of dosing did not affect their
ability to detect TP-induced changes in VP
weight. In most laboratories, no relationships
were found that resulted from differences in
starting body weights and VP weight, and the
laboratory-to-laboratory variability in VP
weights was relatively small (R2 = 6.6%). In
the pooled analysis, all TP doses led to a sig-
niﬁcant increase in VP weight. The phase 1A
VP results are presented graphically both as
absolute weights and relative to the vehicle
control in Figure 1.
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increases in the SVCG weights in all laborato-
ries. Even at the lowest dose of 0.1 mg
TP/kg-bw/day, the SVCG weights differed sig-
niﬁcantly from the controls except in labora-
tory 7 when analyzed using both statistical
approaches, and the laboratory-to-laboratory
variability in SVCG weights was relatively
small (R2 = 6.2%). For the SVCG, differences
among the starting body weights of the animals
contributed to 54% of the interlaboratory vari-
ability. However, these differences and differ-
ences in animal strains did not affect the ability
of the SVCG to respond to TP. In the pooled
analysis, all TP doses led to signiﬁcant increases
in SVCG weights.
LABC results. There were dose-dependent
increases in the LABC weights in all laborato-
ries. At the lowest dose of 0.1 mg/kg-bw/day,
the LABC was statistically significant in all
laboratoies using the t-test approach and in
almost all laboratories using the Dunnett’s
approach. In laboratory 2, the LABC was mar-
ginally statistically significant by Dunnett’s
approach using the starting body weights as
the covariate, but not with the terminal body
weights. In laboratory 9, the LABC was not
signiﬁcant using the Dunnett’s approach. As
noted below, TP administration tended to
increase body weights.
There was a deviation from the protocol in
four laboratories. In these laboratories, only the
levator ani muscle, and not the bulbocaver-
nosus muscle, was dissected. This protocol
deviation did not affect the laboratories’ abili-
ties to detect weight increases in response to
TP but was a source of a significant labora-
tory-to-laboratory variability when all labora-
tories were pooled (R2 = 36%). In the pooled
analysis, all TP doses led to a significant
increase in LABC weights regardless of the
dissection procedure used.
GP results. There were dose-dependent
increases in the GP weights in all laboratories,
but the absolute and relative effects were smaller
than for the other androgen-dependent tissues
examined. Despite this, the GP weights were
statistically different from the controls at the
lowest dose of 0.1 mg TP/kg-bw/day, except in
laboratory 4 when analyzed by either statistical
approach and in laboratory 2 when using the
Dunnett’s but not the t-test approach. There
was a signiﬁcant laboratory-to-laboratory effect
in the responses (R2 = 36%). Laboratories 3 and
4 castrated the animals before PND 40
(PND 38 and PND 31, respectively) before
preputial separation had occurred. In the
pooled analysis, all TP doses led to signiﬁcant
increases in GP weight.
COWS results. There were dose-dependent
increases in the COWS weights in all laborato-
ries. At the lowest dose of 0.1 mg/kg-bw/day,
the weights were statistically signiﬁcant except
in laboratory 4. In laboratory 2, the weight
increase was marginally statistically signiﬁcant
by the t-test and Dunnett’s tests when the
starting body weights were used as the covari-
ate, but not when the terminal body weights
were used. The COWS weights had higher
CVs than the other tissues. Because CVs were
greatest in the vehicle group where the absolute
weights were the smallest, the excision and
weighing of the small COWS tissues may be
technically demanding. In the pooled analysis,
all TP doses led to a significant increase in
COWS weights.
Results of other studies and analyses. Two
laboratories tested whether the corn oil itself
could induce weight changes in the accessory
sex tissues by including an untreated control
group for comparison with the vehicle control
group that received 0.5 mL corn oil/kg-bw.
There were no effects on androgen-responsive
tissues, other organ weights, or total body
weights as a result of corn oil administration
(data not shown).
There were dose-related weight changes in
tissues other than those in the sex accessory
organs. There were small, dose-related absolute
increases in body weights with the TP treat-
ment. These increases were consistent across all
laboratories, but none achieved statistical sig-
niﬁcance (data not shown). Overall, there were
increases in absolute kidney and liver weights
as a function of TP dose, and a dose-related
reduction in absolute adrenal weights (data not
shown). However, these weight changes in
these tissues did not achieve statistical signiﬁ-
cance in any of the laboratories. Overall liver
and kidney weight CVs were 7.8 and 7.3%,
respectively, whereas the adrenal weight CV
was 12.3%, suggesting that adrenal dissection
was more technically challenging.
All but one of the laboratories compared
the weights of fresh and subsequently fixed
(24-hr) VP. Three laboratories performed
additional experiments to examine ﬁxation of
the SVCG and COWS, and one laboratory
weighed the ﬁxed adrenal glands. Fixation did
not affect or improve the ability of any labora-
tory to detect dose-related increases in tissue
weights at any of the TP doses (data not
shown). After a discussion of these results, the
VMG agreed to continue investigating the util-
ity of fixation and included the fixed VP
weight end point in the phase 1B protocol.
Two laboratories also and weighed the
freshly excised the dorsolateral prostate, and
three laboratories also weighed the ﬁxed tissue.
As with the other male sex accessory tissues,
there was a signiﬁcant dose-related increase in
the weights of both the fresh and ﬁxed dorso-
lateral prostate at all TP doses (data not
shown). The VMG discontinued the work
with the dorsolateral prostate and did not
include it in the phase 1B protocol.
Owens et al.
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Figure 1. Response of VP weights to doses of TP (mg/kg-bw/day) in phase 1A. (A) Relative (fold) increases in the VP weights in all participating laboratories in
surgically castrated male rats with TP dosing (subcutaneous) for 10 consecutive days and necropsy on day 11. (B) Absolute increases in the VP weights in all
participating laboratories in surgically castrated male rats with TP dosing (subcutaneous) for 10 consecutive days and necropsy on day 11.Four laboratories measured serum T and
luteinizing hormone (LH) levels. The meas-
ured T concentrations were highly variable
within and among laboratories at all levels of
TP dosing. The analytical method was insufﬁ-
cient to detect T increases at the lowest test
dose of 0.1 mg TP/kg-bw/day, where all sex
accessory tissues were signiﬁcantly increased in
weight. Measured LH levels were also highly
variable and less sensitive than the tissue
weights to TP levels (data not shown).
Therefore, the VMG discontinued the work
with serum T and LH levels in phase 1B.
BMDs were calculated for each tissue within
each laboratory and across laboratories. The
across-laboratories BMDs are reported for each
tissue along with the average CV (Table 2). In
phase 1A, the BMDs for all tissues were within
a 2- to 3-fold range, although the BMDs for
the VP, SVCG, and COWS were somewhat
lower than for the LABC and GP, whereas the
CVs for the VP, SVCG, and COWS were
higher than the LABC and GP (Table 2).
Results of Phase 1B: 
Co-Administration of 
Selected FLU Doses with
Reference TP Doses
In phase 1B, seven laboratories examined the
ability of FLU to block the androgenic
responses to TP. Four of the laboratories used
doses of 0.2 and 0.4 mg, two laboratories used
only 0.2 mg, and one laboratory used only
0.4 mg TP/kg-bw/day. All laboratories pro-
vided summaries of the protocols used and
detailed Excel spread sheets containing the pro-
tocol information and test data. The laboratory
means and standard deviations for each tissue
for phase 1B are provided in Supplemental
Material (http://www.ehponline.org/docs/
2006/8751/suppl.pdf).
VP results. FLU signiﬁcantly inhibited the
effects of 0.2 and 0.4 mg TP/kg-bw/day on
the VP in all laboratories in a dose-related
manner. In animals treated with 0.2 TP
mg/kg-bw/day, FLU signiﬁcantly reduced the
TP-stimulated VP weight gain at either 0.3 or
1 mg FLU/kg-bw/day depending on the statis-
tical approach used. With 0.4 mg TP/kg-bw/
day, using the t-test statistical approach, FLU
induced a significant reduction in the TP-
stimulated VP weight gain at doses between
0.1 and 1.0 mg/kg with the t-test statistical
approach, and between 0.3 and 3 mg FLU/
kg-bw/day with Dunnett’s test. At 10 mg
FLU/kg-bw/day, the absolute VP weights
approached the vehicle control (no TP)
weights. In the pooled analyses, VP weight
was significantly decreased at the 0.2-mg
TP/kg-bw/day dose at 0.3 mg FLU/kg-bw/
day and above. At 0.4 mg TP/kg-bw/day, the
VP weight was significantly decreased at
0.1 mg FLU/kg-bw/day and above. The VP
results for phase 1B are presented graphically
in Figure 2, both as absolute weights and
relative to the vehicle control.
SVCG results. FLU signiﬁcantly inhibited
the effects of 0.2 and 0.4 mg TP/kg-bw/day on
the SVCG in all laboratories in a dose-related
manner. With both 0.2 and 0.4 mg TP/kg-
bw/day, FLU induced a signiﬁcant reduction
in the stimulated VP weight gain between
doses of 0.1 and 1 mg FLU/kg-bw/day, regard-
less of the statistical approach used. At 10 mg
FLU/kg-bw/day, the absolute SVCG weights
approached the vehicle control (no TP)
weights. In the pooled analysis, the SVCG
weight was significantly decreased at 0.3 mg
FLU/kg-bw/day and above in both the 0.2 and
0.4 mg TP/kg-bw/day groups.
LABC results. FLU signiﬁcantly inhibited
the effects of 0.2 and 0.4 mg TP/kg-bw/day on
the LABC in all laboratories in a dose-related
manner. With 0.2 mg TP/kg-bw/day, FLU
induced a signiﬁcant reduction in the TP-stim-
ulated LABC weight gain in laboratory 5 at a
dose of 0.3 mg FLU/kg-bw/day when the t-test
was used. Otherwise, signiﬁcance was reached
only 1 mg/kg-bw/day; however in labora-
tory 13, the Dunnett’s test indicated marginal
signiﬁcance when starting weights were used,
but not terminal weights, which had decreased.
With 0.4 mg TP/kg-bw/day, FLU induced a
signiﬁcant reduction in the stimulated LABC
weight gain between doses of 0.3 and 1 mg
FLU/kg-bw/day regardless of the statistical
approach used. At 10 mg FLU/kg-bw/day, the
absolute LABC weights approached the vehi-
cle control (no TP) weights. In the pooled
analysis, LABC weight was significantly
decreased at 0.3 mg FLU/kg-bw/day and
above in the 0.2 mg TP/kg-bw/day groups
and at the lower 0.1 mg FLU/kg-bw/day dose
and above with the 0.4 mg TP/kg-bw/day
groups.
GP results. FLU signiﬁcantly inhibited the
effects of 0.2 and 0.4 mg TP/kg-bw/day on
the GP in all laboratories in a dose-related
manner. With 0.2 mg TP/kg-bw/day, FLU
induced a signiﬁcant reduction the TP-stimu-
lated GP weight gain over a rather wide range
from 0.1 and 3 mg FLU/kg-bw/day. The
weights in laboratories 15 and 17 reached sta-
tistical significance at the lower FLU doses,
where the GP weights in the TP-only group
had higher starting weights. With 0.4 mg
TP/kg-bw/day, FLU induced a significant
reduction in the stimulated GP weight gain in
the dose range of 1–3 mg FLU/kg-bw/day. At
10 mg FLU/kg-bw/day, the absolute GP
weights approached the vehicle control (no
TP) weights. In the pooled analysis, GP weight
gain was significantly decreased at 0.3 mg
FLU/kg-bw/day and above in the 0.2 mg
TP/kg-bw/day groups, and beginning with the
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Table 2. BMDs (mg TP/kg-bw/day) for male sex
accessory tissues in phase 1A.
BMD (95% lower
conﬁdence limit on the BMD)  Average
Log10 “Correct” CV
Tissue transformation transformationa (%)
VP 0.066 (0.061) 0.089 (0.080)b 23.67
SVCG 0.083 (0.077) 0.120 (0.107)c 20.04
LABC 0.184 (0.152) 0.310 (0.256)b 12.92
GP 0.226 (0.196) 0.256 (0.189)b 12.79
COWS 0.079 (0.0676) 0.129 (0.112)c 22.62
aIf the untransformed or a square-root transformation
gave a larger (nonsignificant) p-value for normality using
Wilk-Shapiro, then the alternative transformation was
applied and a BMD on that data set was calculated.
bUntransformed data. cSquare-root transformation.
Figure 2. Response of VP weight to a reference dose of 0.4 mg TP/kg-bw/day with co-administration of FLU doses (mg/kg-bw/day) in phase 1B. (A) Relative (fold)
decreases in the VP in all participating laboratories in surgically castrated male rats with a TP reference dose (subcutaneous) and co-administration of FLU
doses (oral gavage) for 10 consecutive days and necropsy on day 11. (B) Absolute decreases in the VP in all participating laboratories in surgically castrated
male rats with TP (subcutaneous) and co-administration of FLU doses (oral gavage) for 10 consecutive days and necropsy on day 11.
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COWS results. FLU signiﬁcantly inhibited
the effects of 0.2 and 0.4 mg TP/kg-bw/day on
the COWS in all laboratories in a dose-related
manner. With 0.2 TP mg/kg-bw/day, FLU
induced a signiﬁcant reduction the TP-stimu-
lated COWS weight gain between of 0.3 and
3 mg/kg-bw/day. With 0.4 mg TP kg-bw/day,
FLU induced a significant reduction in the
stimulated COWS weight gain in the dose
range of 0.1–3 mg FLU/kg-bw/day. At 10 mg
FLU/kg-bw/day, the absolute COWS weights
approached the vehicle control (no TP) weights.
In the pooled analysis, COWS weight was sig-
nificantly decreased at 0.1 mg FLU/kg-bw/
day and above in the 0.2 mg TP/kg-bw/day
groups and at the 0.3 mg FLU/kg-bw/
day and above doses in the 0.4 mg TP/kg-bw/
day groups.
Results of other measurements. As in
phase 1A, treatment of the rats with 0.2 or
0.4 mg TP/kg-bw/day for 10 days resulted in
low, but consistent, absolute body weight gains
that were not statistically signiﬁcant at either
dose (data not shown). The administration of
FLU to the TP-treated rats led to lower body
weights than in the TP-only treated animals
after the 10-day treatment period, but the dif-
ferences were not statistically signiﬁcant (data
not shown). FLU treatment did not affect the
modest absolute increases in liver and kidney
weight gains induced by TP, but FLU treat-
ment mitigated the TP-induced decrease in
adrenal weight gains in a dose-related manner
(data not shown). All increases in recorded
adrenal weight were significant at the
10 mg/kg-bw/day FLU dose.
Several laboratories in phase 1B continued
to compare the impact of ﬁxation on the VP
weights. Statistical analyses of the fixed VP
weights resulted in the same dose–response sen-
sitivity as the fresh VP weights, and ﬁxation of
the VP did not consistently affect the CV of the
measurement within or among laboratories.
The sensitivities of each of the tissues to
FLU inhibition of TP-induced weight gain in
phase 1B were evaluated using the BMD
approach. The BMDs for all tissues were
within a 2- to 3-fold range, and the BMDs did
not consistently favor either the 0.2 or 0.4 mg
TP/kg-bw/day reference doses (Table 3).
Discussion and Conclusions
The regulatory need for the Hershberger bio-
assay is to identify and to assist in the prioriti-
zation of test substances that may have an
androgenic or antiandrogenic mechanism of
action. The androgen receptor is the molecular
starting point for both adverse effects in the
male reproductive tract during in utero devel-
opment and the control of growth responses of
the male sex accessory tissues (as measured in
the Hershberger bioassay). Further, a sub-
stance’s androgen receptor afﬁnity and com-
plex absorption, transformation, distribution,
and excretion processes should be sufﬁciently
similar between in utero and peripubertal expo-
sures to support the relevance of the assay as an
in vivo screen for regulatory concerns. The
short time frame of the test and the limited
number of animals needed lend further sup-
port to the assay. These rationales for the regu-
latory use of the Hershberger assay have been
broadly supported in scientific workshops
(European Commission/OECD 1997; Gray
et al. 1997).
The primary purpose of this phase 1 vali-
dation effort was to test the robustness and
reproducibility of the Hershberger protocol
developed for the OECD. In that regard, the
data presented here support the conclusion
that the Hershberger assay is measuring rele-
vant biological responses; that it is sufﬁciently
sensitive, robust, and reproducible to detect
androgenic and antiandrogenic activities; and
that the protocol is adequate to proceed to the
next phase of validation. All laboratories were
successful in detecting changes in the weights
of TP-stimulated male sex accessory glands
with the standardized protocol, and the inhibi-
tion of weight gain in TP-stimulated tissues
when the antagonist FLU was co-administered.
In phase 1A, all ﬁve of the androgen-sensitive
sex accessory tissues increased in weight as a
function of TP dose in all laboratories. In
phase 1B, the antagonistic activity of FLU to
TP was detectable in all ﬁve of the androgen-
sensitive sex accessory tissues in a dose-related
manner with both reference doses of TP. The
use of six animals per dose group was sufﬁcient
to robustly detect the androgenic and anti-
androgenic activity of potent substances.
The next phase of the validation program
will determine if six animals per group will be
sufﬁcient for detecting weaker androgens and
antiandrogens. The ability of the protocol to
detect these changes was not affected by differ-
ences in rat strain, diet, caging, routine labora-
tory procedures, and modest differences in the
ages at which the animals were castrated. The
data did suggest that the animals should be cas-
trated after preputial separation occurs (usually
after 42 days). When the animals were cas-
trated earlier, the GP was not fully separated
from the prepuce in some laboratories, making
it more difﬁcult to dissect and increasing the
CV in these cases.
The use of slightly different statistical
approaches to analyze the data yielded con-
sistent results. As was expected, the t-test
approach was occasionally able to reach statisti-
cal signiﬁcance when the Dunnett’s approach
remained marginally insignificant. The test
results were also evaluated further by an inde-
pendent statistician, and the statistical out-
comes and results were reproducible. The
independent analysis tested the ANOVA
assumptions, that is, that the error terms are
independently normal with constant variance.
Because only a log transformation was used
originally, the independent analysis also investi-
gated the use of untransformed data or a
square-root transformation procedure. Among
the various transformations examined, the 
log transformation was the best overall method.
However, data transformation was not neces-
sary in all cases, and no single transformation
was consistently better in normalizing the data
across all laboratories and end points [Supple-
mental Material (http://www.ehponline.org/
docs/2006/8751/suppl.pdf)]. In a few isolated
cases, the lowest observed effect level (LOEL)
value changed when the more appropriate
transformation procedure (i.e., absence of trans-
formation in all cases) rather than log transfor-
mation was used [Supplemental Material
(http://www.ehponline.org/docs/2006/8751/
suppl.pdf)]. Such changes were few and minor,
the LOELs remained consistent across laborato-
ries and end points, and the additional inde-
pendent statistical analysis supports the claim
that the Hershberger assay is robust.
The utility and sensitivity of the ﬁve man-
datory sex accessory tissues were evaluated.
Statistical signiﬁcance is used to yield a LOEL
dose, and statistical significance is largely
determined by a combination of the degree or
Owens et al.
1264 VOLUME 114 | NUMBER 8 | August 2006 • Environmental Health Perspectives
Table 3. BMDs (mg FLU/kg-bw/day) for male sex accessory tissues in phase 1B.
BMD (95% lower conﬁdence limit on the BMD)
Tissue TP dose (mg/kg-bw/day) Log10 transformation “Correct” transformationa Average CV (%)
VP 0.2 0.603 (0.512) 0.499 (0.418)b 20.87
0.4 0.609 (0.525)
SVCG 0.2 0.542 (0.477) 20.93
0.4 0.510 (NA) 0.311 (0.271)b
LABC 0.2 1.115 (1.007) 0.917 (0.790)b 11.35
0.4 0.501 (NA) 0.293 (0.240)c
GP 0.2 0.502 (NA) 0.332 (0.218)c 9.36
0.4 1.308 (NA) 1.067 (0.825)b
COWS 0.2 1.333 (NA) 19.69
0.4 0.948 (0.737)
NA, lower bound computation did not converge. 
aIf the untransformed or a square-root transformation gave a larger (nonsignificant) p-value for normality using Wilk-
Shapiro, then the alternative transformation was applied and a BMD on that data set was calculated. bSquare-root trans-
formation. cUntransformed data.percentage of change, and the degree of vari-
ability, in the measurement. First, these tissues
undergo very different overall relative changes
in weight from > 10-fold (1000%) for the
VP and the SVCG) to 80–120% for the
GP [Supplemental Material (http://www.
ehponline.org/docs/2006/8751/suppl.pdf)].
Second, the tissues differ in size, whether they
contain fluid, and other aspects related to
potential difﬁculties and variability during tis-
sue dissection, handling, and weighing. These
differences should be collectively described by
the CV value for the different tissues, and these
values vary considerably. The CVs for starting
and terminal body weights and the ﬁve manda-
tory sex accessory tissues have been summa-
rized for phase 1A and phase 1B, leading to
three conclusions: a) the CVs for fluid-filled
tissues (VP, SVCG, COWS) are approxi-
mately double those for the solid tissues
(LABC and GP), and b) some laboratories
consistently have lower CVs, suggesting proﬁ-
ciency differences in dissection. Similar associa-
tions of CV and laboratory proficiency have
been noted during the uterotrophic validation
(Kanno et al. 2001, 2003). In the case of the
male sex accessory tissues themselves, the tis-
sues with the highest responses also have the
highest CVs, and vice versa, which suggests
that no large differences in sensitivity may exist
among the tissues.
An evaluation of the LOELs for the differ-
ent tissues supports this hypothesis. No dra-
matic differences were noted in the LOELs of
the different tissues. In phase 1A, except for
laboratories with relatively high CVs, all tissues
achieved statistical significance at the lowest
TP dose of 0.1 mg/kg-bw/day. In phase 1B,
the tissues achieved statistical signiﬁcance in a
similar range of FLU doses, and most LOELs
were in 0.3–1 mg FLU/kg-bw/day range with
either 0.2 or 0.4 mg TP/kg-bw/day as the ref-
erence dose [Supplemental Material (http://
www.ehponline.org/docs/2006/8751/suppl.
pdf)]. When the tissues are compared by the
number of times they provided or were coinci-
dent in providing the LOEL dose, the VP did
so in three instances, the SVCG in six instances,
the LABC once, the GP once, and the COWS
in four instances.
BMDs were calculated for each tissue
along with its average CV for phase 1A
(Table 2) and phase 1B (Table 3). The BMDs
were somewhat lower for the VP, SVCG, and
COWS than the LABC and GP in phase 1A
but were not distinguishable overall in
phase 1B. Therefore, without compelling
technical support that one tissue is distinctly
less sensitive than the others, all five tissues
will continue to be required in the phase 2
protocol using additional agonist and antagonist
test substances.
In terms of the other measurements and
procedures, no added value could be attributed
to measurements of the dorsolateral prostate,
the ﬁxation of any of the tissues, or serum hor-
mone (T or LH) analyses. Therefore, these
measures will not be included in phase 2 of the
validation program. Liver, kidney, and adrenal
weights will be retained as optional measure-
ments in phase 2.
To summarize, all laboratories were
successful in detecting increases in androgen-
responsive tissue weights using TP, and
decreases in TP stimulated tissue weight when
FLU was co-administered. The basic protocols
performed well under a variety of different
laboratory conditions (e.g., strain, diet, hous-
ing protocol, bedding, vehicle). There was
good agreement among laboratories with
regard to the lowest effect TP doses inducing
significant increases in tissue weights and to
the FLU doses inducing decreases in TP-
stimulated tissue weights. Several additional
procedures (e.g., fixation of certain tissues
before weighing) and serum component mea-
surements (e.g., serum hormones) were also
included in these studies to assess their poten-
tial utility but have not been included in the
ﬁnal protocols.
In conclusion, the results indicated that the
OECD Hershberger protocols were robust,
reproducible, and transferable across laborato-
ries when using high-potency compounds such
as TP and FLU. The protocols have been
reﬁned, and the next phases of the OECD vali-
dation program will test the protocol with
selected doses of weak androgen agonists,
androgen antagonists, a 5α-reductase inhibitor,
and chemicals having no androgenic activity.
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